• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.

作者信息

Georgakopoulos Jorge R, Phung Michelle, Ighani Arvin, Yeung Jensen

机构信息

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Am Acad Dermatol. 2018 Jul;79(1):155-157. doi: 10.1016/j.jaad.2018.01.003. Epub 2018 Jan 4.

DOI:10.1016/j.jaad.2018.01.003
PMID:29307635
Abstract
摘要

相似文献

1
Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.在使用司库奇尤单抗治疗无效的斑块状银屑病患者中换用依奇珠单抗的疗效与安全性：一项关于白细胞介素17A拮抗剂疗法的多中心回顾性研究
J Am Acad Dermatol. 2018 Jul;79(1):155-157. doi: 10.1016/j.jaad.2018.01.003. Epub 2018 Jan 4.
2
IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.白细胞介素 17A 抑制剂转换 - 司库奇尤单抗治疗失败后使用依奇珠单抗的疗效。一项单中心经验。
Acta Derm Venereol. 2019 Jul 1;99(9):769-773. doi: 10.2340/00015555-3200.
3
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
4
Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.司库奇尤单抗和依奇珠单抗治疗中重度斑块型银屑病的药物生存情况。
J Am Acad Dermatol. 2019 Jul;81(1):173-178. doi: 10.1016/j.jaad.2019.03.048. Epub 2019 Mar 23.
5
Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.白细胞介素-17（IL-17）抑制剂治疗斑块状银屑病的综述
Skin Therapy Lett. 2015 Jan-Feb;20(1):1-5.
6
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.抗白细胞介素-17 单克隆抗体依奇珠单抗治疗慢性斑块状银屑病。
N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.
7
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).在依那西普无反应者中转换为司库奇尤单抗的疗效和安全性：来自两项中重度斑块状银屑病III期随机临床试验（UNCOVER-2和-3）的亚组分析
Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9.
8
IL-17 inhibitors for psoriasis.用于治疗银屑病的白细胞介素-17抑制剂
Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.
9
Real-world drug survival of ixekizumab for psoriasis.司库奇尤单抗治疗银屑病的真实世界药物留存率
J Am Acad Dermatol. 2019 Jul;81(1):270-272. doi: 10.1016/j.jaad.2019.01.034. Epub 2019 Jan 26.
10
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.司库奇尤单抗改善环孢素 A 应答不足的银屑病患者的症状：评估直接转换的前瞻性研究。
J Dermatol. 2017 Oct;44(10):1105-1111. doi: 10.1111/1346-8138.13911. Epub 2017 May 23.

引用本文的文献

1
Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study.斑块状银屑病患者从司库奇尤单抗转换为依奇珠单抗治疗的疗效与安全性：一项多中心回顾性研究
J Pers Med. 2024 Dec 22;14(12):1169. doi: 10.3390/jpm14121169.
2
A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis.一项关于司库奇尤单抗治疗后使用依奇珠单抗治疗活动性银屑病关节炎患者有效性的回顾性研究。
J Psoriasis Psoriatic Arthritis. 2022 Jan;7(1):13-16. doi: 10.1177/24755303211063841. Epub 2021 Dec 20.
3
Colitis induced by IL-17A-inhibitors.
由 IL-17A 抑制剂引起的结肠炎。
Clin J Gastroenterol. 2024 Apr;17(2):263-270. doi: 10.1007/s12328-023-01893-9. Epub 2023 Dec 7.
4
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class.近期古塞库单抗治疗失败的斑块状银屑病患者中瑞莎珠单抗的真实世界有效性和安全性：一项白细胞介素-23抑制剂类药物转换的多中心回顾性研究
JAAD Int. 2023 May 26;12:136-138. doi: 10.1016/j.jdin.2023.05.006. eCollection 2023 Sep.
5
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.在CorEvitas银屑病登记处中接受司库奇尤单抗和其他生物制剂治疗的司库奇尤单抗患者的治疗结果。
Dermatol Ther (Heidelb). 2022 Dec;12(12):2797-2815. doi: 10.1007/s13555-022-00834-7. Epub 2022 Nov 4.
6
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.白细胞介素-17与白细胞介素-23：银屑病及其相关合并症作用机制的叙述性综述
Dermatol Ther (Heidelb). 2021 Apr;11(2):385-400. doi: 10.1007/s13555-021-00483-2. Epub 2021 Jan 29.
7
Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study.司库奇尤单抗在接受过大量治疗的银屑病患者中的生存情况：一项为期两年的单中心回顾性研究。
Acta Derm Venereol. 2020 Dec 14;100(19):adv00349. doi: 10.2340/00015555-3714.